Functional Cannabinoids Explained: CBG, CBC, CBDV and the New Wave Beyond CBD

Ship to
Functional cannabinoids are the reason the hemp world is sprinting beyond CBD, and yes, it’s happening on purpose.
For years, CBD did all the heavy lifting. It became the default. The safe bet. The thing your aunt put in her coffee and your gym buddy rubbed on his knees.
Now the market is growing up. Brands are building formulas with multiple non-intoxicating cannabinoids, each chosen for a specific job. Not because it sounds cool on a label, but because consumers are asking smarter questions, and because looming regulatory pressure is making “intoxicating hemp” a risky business model.
If you keep hearing terms like CBG, CBC, CBDV, and THCV and thinking, “Great, more alphabet soup,” good. You’re paying attention. Let’s turn the soup into something you can actually use.
Let’s define the category before we get seduced by acronyms.
Functional cannabinoids (often called “minor cannabinoids”) are naturally occurring compounds from the cannabis/hemp plant that are typically found in smaller amounts than CBD or THC. “Functional” is the industry’s way of saying:
Important reality check: the research on many minor cannabinoids is early. Some have promising preclinical data (cells, animals). Some have small human studies. Some have “we’re getting there” vibes. That doesn’t mean they do nothing. It means you should shop like an adult, not like a late-night infomercial enthusiast.
Three forces are pushing this category forward:
CBD is everywhere. When everything is “premium CBD,” nothing is. Brands needed differentiation, and consumers needed better outcomes than “maybe I feel something, maybe I don’t.”
Early hemp products were basically “CBD + hope.” Now brands stack cannabinoids with terpenes and supportive botanicals and actually think about dosage, delivery, and purpose.
A major reason this category is booming is simple: the market is being pushed away from intoxicating cannabinoids and toward functional, non-intoxicating ones. With the Nov 2026 law expected to reshape what’s viable for hemp brands, many companies are planning ahead. That means fewer business models built around “how close can we get to THC,” and more built around “how well can we deliver wellness without intoxication.”
Translation: functional cannabinoids are becoming the new safe lane. And everyone is merging into it at once.
Cannabinoids interact with a network in your body often called the endocannabinoid system (ECS), which plays a role in regulating things like mood, sleep, stress response, discomfort, appetite, and inflammation signaling.
Two key points you should tattoo on your shopping hand:
Now, let’s meet the main characters.
CBG (cannabigerol) is often called the “mother cannabinoid” because it’s a precursor compound in the plant that can convert into other cannabinoids as the plant matures.
What you actually care about: CBG is commonly used for daytime formulations because many people report it feels more “clear” and “functional” than CBD.
CBG has been studied in preclinical settings for a range of properties, including anti-inflammatory and analgesic potential, and there’s growing interest in how it may influence mood and stress pathways. There is also early investigation into gut-related mechanisms and other targets beyond the classic cannabinoid receptors.
Be precise here: we do not have mountains of large-scale human trials proving specific outcomes for CBG products on store shelves. We do have enough mechanistic and preclinical signals to justify why formulators are excited, and enough consumer experience to explain why it’s selling.
Because CBG lets them build products that feel:
Also, it’s harder to source in high concentrations because hemp typically contains low natural CBG. That scarcity can be a blessing for premium branding and a curse for your wallet.
CBC (cannabichromene) does not get the spotlight it deserves, mostly because it isn't as famous and it doesn't have the same meme energy as "CBD" or "THC."
That's a shame, because CBC is one of the more interesting "support cannabinoids" in modern formulas.
CBC has been explored in preclinical research for anti-inflammatory and analgesic properties. It also appears to interact with targets involved in pain and inflammation pathways, and it is frequently discussed in the context of the "entourage effect," where multiple cannabinoids together may produce broader effects than one alone.
On mood: there's interest in how CBC might influence pathways related to emotional regulation, but again, keep your feet on the ground. The strongest claims are not yet backed by large human clinical trials.
Because CBC is a team player. It’s commonly used to:
If CBD is the lead singer, CBC is the guitarist who quietly makes the whole band sound better.
CBDV (cannabidivarin) is where things get interesting, because it’s not just a trendy new ingredient. CBDV has been studied for neurological and behavioral applications, and it has attracted genuine scientific attention.
It is also a perfect example of why this “beyond CBD” wave is happening: brands want cannabinoids that can be positioned around specific functional categories, and CBDV fits into a “brain and nervous system” conversation.
You’ll also see it pop up in “daily balance” or “neuro-support” style formulas.
CBDV has been investigated in relation to seizure and neurodevelopmental conditions, with clinical and preclinical exploration over the years. Interest centers on how CBDV may influence signaling pathways beyond CB1/CB2, including channels involved in neuronal excitability.
Be careful with the leap from “studied for X in a medical context” to “this gummy treats X.” That leap is where marketing gets sloppy and regulators get cranky.
THCV (tetrahydrocannabivarin) is the one that gets whispered about like a “diet weed” secret. That reputation is partly based on real pharmacology and partly based on internet exaggeration, which is basically the official language of wellness trends.
THCV can be non-intoxicating at lower doses for many people, but it is more structurally related to THC than the others on this list. Effects can depend heavily on dose and the product’s full cannabinoid profile.
THCV has been studied for potential effects related to metabolic health and appetite regulation, and it interacts with cannabinoid receptors in a dose-dependent way. That dose dependency is the key detail many labels conveniently ignore.
Because it offers a functional lane that CBD doesn’t own: energy, motivation, appetite discipline. It also sells well because the promise is easy to understand. People love two things: snacks, and not wanting to want snacks.
You’ll hear “entourage effect” tossed around constantly. Here’s the grounded version:
Cannabinoids can influence each other’s perceived effects, and terpenes may contribute to the overall experience. That’s why brands increasingly create formulas like:
Is every blend perfectly designed? No. Some are just label decoration. But good formulations are not random. They’re built for repeatable, purpose-driven outcomes.
You don’t need a biochemistry degree. You need a checklist and a little skepticism.
Don’t buy “the newest cannabinoid.” Buy the cannabinoid that matches your intent.
A legitimate product should have third-party testing that confirms:
If the COA is missing, outdated, or doesn’t list the cannabinoids being marketed, that’s your cue to leave.
“Infused with CBG” is not a dosage. It’s a vibe.
Look for:
Then actually do the math. Yes, you must. No, the brand will not do it for you.
Minor cannabinoids can feel subtle until they don’t. Begin with a conservative amount, give it time, and only then adjust.
Also: keep notes. Treat it like a tiny personal experiment, not a dramatic quest.
The “wave beyond CBD” is not a passing fad. It’s a category shift.
As regulation tightens and brands move away from intoxicating hemp cannabinoids, you’ll see more:
Your job is simple: buy the purpose, verify the proof, respect the dose. Do that and functional cannabinoids stop being confusing. They become tools.
CBD opened the door, but functional cannabinoids are furnishing the whole house.
Don’t chase buzzwords. Chase transparency. Read the COA. Pick a goal. Start low. Go slow.
And welcome to the wave beyond CBD. It’s bigger, smarter, and a little cheekier than the first one.
Functional cannabinoids, often called "minor cannabinoids," are naturally occurring compounds in the cannabis/hemp plant found in smaller amounts than CBD or THC. Unlike CBD, which has been the default cannabinoid for years, functional cannabinoids are selected for specific effect profiles such as focus, mood, inflammation response, and appetite. They are generally non-intoxicating or low-intoxicating and used in formulations alongside other cannabinoids and botanicals to deliver targeted wellness benefits.
The hemp market is evolving beyond CBD due to three main forces: 1) CBD has become crowded and commoditized, making differentiation difficult; 2) Advances in formulation science now allow brands to combine multiple cannabinoids with terpenes and botanicals for more effective products; 3) Regulatory pressures, especially upcoming laws by November 2026, are pushing brands away from intoxicating cannabinoids towards safer, functional, non-intoxicating options. This shift is driving growth in the use of minor cannabinoids for specific wellness purposes.
Functional cannabinoids interact with the body's endocannabinoid system (ECS), which regulates mood, sleep, stress response, discomfort, appetite, and inflammation. Each cannabinoid has different affinities and mechanisms of action within this system. Because many functional cannabinoids are non-intoxicating or low-intoxicating, they provide targeted effects like focus or inflammation support without the psychoactive effects associated with THC. Effects also depend on dosage, delivery method (e.g., gummy vs tincture), and the overall formulation.
CBG (cannabigerol) is known as the "mother cannabinoid" because it serves as a precursor compound in the cannabis plant that converts into other cannabinoids like CBD and THC as the plant matures. CBG is favored in daytime formulations because users report it provides a clear, functional feeling without intoxication. It supports daytime calm, focus, mental clarity, physical comfort, and recovery without causing sedation.
Early preclinical research on CBG indicates potential anti-inflammatory and analgesic properties. There is growing interest in its influence on mood and stress pathways as well as gut-related mechanisms beyond classic cannabinoid receptors. However, large-scale human clinical trials are limited at this time. The promising mechanistic data combined with consumer experiences justify its increasing use in formulations aimed at focus and wellness.
When shopping for CBG products, look for meaningful doses typically ranging from 5–20 mg per serving or higher depending on your needs. Choose formats based on your goals: tinctures offer faster onset and precise dosing control while gummies or capsules provide slower absorption. Because high-concentration CBG can be scarce and pricier due to low natural levels in hemp plants, prioritize reputable brands that transparently disclose dosages and formulation details to avoid being misled.